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Abstract
Publications relating esophageal radiation toxicity to clinical variables and to quantitative dose
and dose–volume measures derived from three-dimensional conformal radiotherapy for non–
small-cell lung cancer are reviewed. A variety of clinical and dosimetric parameters have been
associated with acute and late toxicity. Suggestions for future studies are presented.
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1. Clinical Significance
Acute esophagitis (occurring ≤90 days after treatment initiation) is a common side effect of
patients undergoing radiotherapy (RT) for thoracic tumors. Concurrent chemoradiotherapy
(CCT) or hyperfractionation results in a 15–25% rate of severe (Radiation Therapy
Oncology Group [RTOG] Grade 3 or greater) acute esophagitis (1–3) that can require
hospitalization, invasive diagnostic tests (e.g., endoscopy), surgical intervention (e.g.,
percutaneous endoscopic gastrostomy tube) or RT breaks that could lower local tumor
control.
Late injury is less commonly reported, perhaps because the patients might not live long
enough to manifest toxicity (e.g., the disease-specific survival is relatively short for many
thoracic cancers). Dose escalation of standard fractionated RT and hypofractionated RT
regimens (4, 5) can increase the risk of late esophageal toxicity, especially if the survival
rates improve. Esophageal stricture often requires periodic dilation, usually with good
results (6). Death related to late esophageal injury (e.g., tracheoesophageal fistula or
esophageal perforation) has been reported in only 0.4–1% of patients (7, 8).
2. Endpoints
The assigned toxicity grade varies with the scoring system used, making interstudy
comparisons challenging. In general, Grade 1 toxicities cause minor changes in a patient's
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lifestyle, and Grade 2 or greater toxicities might require medical intervention. The currently
accepted grading system is the Common Terminology Criteria for Adverse Events, version 3
(9); however, the studies cited in the present report mostly used the RTOG scoring system.
In the present review, Grade 2 or greater acute esophagitis (because it constituted the end-
point of many studies) and any late esophagitis (Grade 1 or greater), independent of the
duration of the late symptoms, were considered clinically significant.
Acute esophagitis occurs during RT and often persists for several weeks after RT. The
symptoms of severe esophagitis (Grade 3 or greater) typically peak 4–8 weeks from the
beginning of RT (10). Late esophageal damage, typically stricture and associated dysphagia,
develops ∼3–8 months (range, 5–40) after RT (11). Abnormal esophageal motility can be
noted within 3–4 weeks from RT alone and as early as 1 week after starting concurrent
chemoradiotherapy (12).
Some of the pitfalls in assigning the acute esophagitis grade are as follows:
1. Esophageal infection can mimic treatment (RT or concurrent chemoradiotherapy)-
related esophagitis. Candidiasis (usually suggested by co-existing oral candidiasis)
or, rarely, herpes simplex esophagitis are the main culprits.
2. Pre-existing gastroesophageal reflux can worsen the symptoms of esophagitis and
should be treated. Constant burning, unrelated to the act of swallowing, and
localized in the lower part of the esophagus is more likely related to the reflux than
to the treatment-related esophagitis.
3. Incidental irradiation of the stomach, and associated gastritis symptoms, can occur
when a lower lobe lung mass has been treated.
4. The assignment of Grade 2 (brief intravenous fluid for ≤24 hours) vs. Grade 3
(hospitalization) esophagitis might be physician-dependent.
3. Challenges Defining Volumes
The adult esophagus length is ≈ 25 cm and is defined by its external contour on axial
computed tomography (CT) images. The esophagus remains closed when not involved in
swallowing, and its lumen is often not easily identifiable throughout its entire length,
particularly in the middle and caudal levels. Administration of a thick barium paste can help
localize the esophagus, but the swallowing times are short (10 seconds), and the barium
paste might not fully opacify the entire organ. In addition, high-contrast barium can affect
the heterogeneity-corrected dose calculations. It is recommended that the entire length of the
esophagus, from the cricoid cartilage to the gastroesophageal junction, be identified,
requiring that a portion of the neck and upper abdomen be included in the planning CT scan.
In some of the studies (8, 11, 13), the cephalad (“cervical”) esophagus was not included,
causing the absolute esophageal volume to be ∼20% smaller than if its entirety had been
contoured.
The esophagus is slightly mobile. In a study of 29 patients undergoing four-dimensional CT
scans three times during RT, the cephalad, middle, and caudal esophagus can move ≤5,7,
and 9 mm in the combined anteroposterior and craniocaudal directions, respectively (14).
Thus, dose–volume analyses using the planning CT scan (as was done in the studies we
reviewed), could have some inaccuracies, although no specific margin recommendations can
be given at this time.
The esophageal circumference varies markedly on sequential axial CT images, a reflection
of the swallowing act. This appearance does not reflect the anatomic reality of a relatively
uniform circumference (15). Thus, conventional dose–volume histograms (DVHs) might not
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accurately reflect the partial volume doses. In the single study to consider this issue, the
predictive value of metrics that were “corrected” for this anatomic reality were slightly
better predictors of outcome than were the “traditional” DVH-based metrics (15).
Nevertheless, the use of alternative three-dimensional dosimetric parameters (e.g., dose–
surface-area, dose–circumference histograms, “anatomically corrected” DVHs) as improved
predictors of outcome is of unclear utility (11, 15, 16).
4. Review of Dose–Volume Published Data
A total 12 studies published between 1999 and January 2009 that assessed the dose–volume
outcome in ≥90 patients treated for non–small cell lung cancer were reviewed (7, 8, 11, 13,
16–19, 20–23) (Table 1). All but one study (17) used three-dimensional planning. The
endpoint was usually RTOG Grade 2 or greater or Grade 3 or greater. Two studies (7, 8)
combined acute and late toxicities in a single analysis. The others either analyzed only acute
(13, 16, 17, 19, 20, 22, 23) or analyzed acute and late toxicity separately (11, 18). The
studies found a correlation with these endpoints for a variety of dose–volume factors.
The maximal esophagus dose had significant univariate correlation (p ≤ .05), with severe
esophagitis in all the studies that included it as a variable (7, 8, 11, 13, 20). However, it only
remained significant in multivariate analyses in some of them (7, 8, 11).
Ten studies (8, 13, 16, 18, 19–24) searched for correlations between severe acute esophagitis
and either the absolute volume (aVdose), absolute area (aAdose), or percentage of a reference
volume (Vdose), or reference area (Adose) receiving more than a specified dose. Eight of
these studies (13, 16, 19–24) found significant univariate correlations with exposure over a
wide dose range (10–80 Gy; Table 1 and Fig. 1). Multivariate analysis (16, 19, 20, 22, 24)
identified fewer dose–volume combinations. Because of the diverse reporting metrics, we
could not find a consensus for the dose–volume thresholds. For example, one study (19)
found V35 was the only dosimetric predictor of RTOG Grade 2 or greater acute esophagitis
on multivariate analysis, both with and without CCT, and another study (22) found V20 to be
the only multivariate significant factor for 215 patients receiving CCT. However, a third
study (16) found a much greater dose region (aA55 and aA80 or aV60 and aV80) to be
significant.
Some studies found circumferential metrics (e.g., esophageal length receiving full
circumference dose >40–66 Gy [19] or 50–65 Gy [11]) to be significant, although not
superior to simpler volume or area metrics.
Four studies (7, 8, 11, 22) found a univariate correlation with the mean dose greater than
levels ranging from 34 Gy (7) to 40 Gy (8). A 34-Gy mean dose recommendation was
adopted in the RTOG Phase III comparison of 60 Gy vs. 74 Gy with CCT in Grade III non–
small-cell lung cancer (RTOG 0617).
Dose–volume histogram parameters describing cumulative dose >50 Gy have been
identified as highly statistically significantly correlated with acute esophagitis in several
studies. Some studies (Fig. 1), however, have shown the strongest statistically significant
correlations with esophagitis at lower doses (as low as V30), perhaps owing to technique
differences. V30 was also implicated in a multivariate modeling study by El Naqa (21).
Overall, the data are consistent with some risk of acute esophagitis at intermediate doses
(30–50 Gy) and an increasing effect for greater doses.
A main obstacle to obtaining definitive dosimetric recommendations from the published data
is the variety of volumetric metrics—the absolute volume or area, relative volume or area,
and circumferential measures—all have been analyzed. Reports describing relative metrics
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might have used different reference volumes (9, 13). Differences in the way other technical
factors were handled have less effect. For example, adjusting DVHs for conventional
fraction size and the type of tissue heterogeneity correction used are likely to have only
minor effect, the latter because the esophagus is embedded in bulky soft tissue and
anteroposterior/posteroanterior beams are the main component in many treatment plans.
Several studies have provide enough information to estimate the incidence of esophagitis to
dosimetric parameters (Fig. 2). There does appear to be a dose–response relationship,
although the interstudy variations have been large. Nevertheless, the data are somewhat
consistent, with rates of acute Grade 2 or greater esophagitis increasing to >30% as V70
exceeds 20%, V50 exceeds 40%, and V35 exceeds 50%.
5. Factors Affecting Risk
Greater acute esophagitis rates are seen with increased RT aggressiveness (e.g.,
hyperfractionation, concurrent boost), the addition of CCT, and several clinical factors (e.g.,
pre-existing dysphagia and increasing nodal stage, with the latter likely a surrogate for larger
tumors; Table 1). The incidence of Grade 3 or greater acute esophagitis is ≈ 1% for patients
treated with once-daily RT alone. It is markedly increased with the addition of CCT
(incidence, 6–24%) and is as great as 49% with concurrent gemcitabine. The Continuous
Hyperfractionated Accelerated Radiation Therapy regimen (25) reported a 19% rate of
severe (Grade 3 or greater) esophagitis. Older patients (>70 years of age) were more likely
than younger patients to experience high-grade esophagitis in a secondary analysis of the
RTOG 94-10 study (26).
Several studies have assessed the putative radioprotector amifostine. Three single-institution
Phase III studies (27– 29) suggested a significant benefit (27, 28) or a trend (29) for
amifostine in lowering Grade 2 or greater esophagitis. However, the findings are difficult to
interpret because of the small patient numbers and low (28) or unknown (27) incidence of
Grade 3 or greater esophagitis. These results were not confirmed in a large cooperative
group Phase III randomized study of 243 patients (RTOG trial 98-01) (30).
6. Mathematical/Biologic Models
Statistical models
The statistical level of correlation between a complication and a set of variables is
inadequate for treatment planning purposes. Statistical models aim to supply the missing
link. They use the most significant dose–volume or dose–area variable and medical factors
(e.g., CCT) as variables in a sigmoidal function. The typical functional form is
The summation (symbolized by Σi) represents a weighted combination of the patient-
specific values of the significant dose–volume variables, Vdosei. CCT can be handled by an
extra term or by having different sets of coefficients for patients with and without CCT. The
model coefficients, ci, are chosen to best match the observed complication rates, and
coefficient values are given in the cited studies. The simplest models (probably too simple)
use a single dose–volume variable (e.g., V35 [19], V20, or mean dose [22]). Others use
several DVH-based variables (e.g., a four-variable model [21] selected absolute area points
with doses from 30 to 85 Gy). Such statistical models are more sensitive to the DVH shape
than those based on a single Vdose point.
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Two recent studies (13, 19) used the maximum likelihood method to find the Lyman-
Kutcher-Burman model parameters that correlated well with the incidence of Grade 2 or
greater acute esophagitis in their respective populations of patients without CCT. Both
studies applied tissue inhomogeneity and linear-quadratic corrections to 2-Gy equivalent
regimens but used different reference esophageal lengths. Chapet et al. (13) excluded the
cervical esophagus; thus, their reference length was approximately 20% shorter than that of
Belderbos et al. (19). Table 2 lists the parameters from these two studies and, for
comparison, the 1991 parameters (31). Because the 1991 endpoint was a very severe and, in
modern times very rare, toxicity of clinical stricture or perforation, it is not surprising that
the 1991 Lyman-Kutcher-Burman parameters are different from those from the more recent
studies for which the endpoint was RTOG Grade 2 or greater acute esophagitis. Both recent
parameterizations (13, 19) yielded mid-size n values, consistent with the correlation with a
wide range of significant dose–volume factors noted in the section, “Review of Dose–
Volume Published Data.” The Lyman parameters of the two studies agreed within their
broad 95% confidence intervals.
Relative Seriality Model
Parameters for relative seriality model were derived (32) from partial irradiation tabulation
of Emami et al. (33). Recent planning study (34) found this model/parameter combination
predicted a complication rate similar to Lyman model using Burman et al. (31) parameters.
However, because both were parameterized to fit the Emami data, neither might be relevant
to the studies and milder endpoints reviewed in section “Review of Dose–Volume Published
Data.”
General comments
Because acute esophagitis events occur mainly during a course of therapy, the rapidity of
dose accumulation might be more important than the final overall dose (much of which is
delivered after the complication risk has peaked). No current models account for the course
of a complication relative to the number of fractions delivered. It also follows that existing
models and dose–volume parameters should not be applied to regimens in which the number
of fractions is much different from 30–35 Gy without careful additional study.
7. Special Situations
Hypofractionation for central lesions can expose parts of the esophagus to relatively large
doses per fraction. Predictions using conventional fractionation should not be applied to
such treatments unless they have been validated by additional study. Although a few reports
have been published of serious esophageal toxicity from hypofractionation (35), no
comprehensive dose–volume-based analyses have been published. Similarly, no large body
of data exists on long-term esophageal toxicity of other altered fractionation schemes (e.g.,
hyperfractionation; in-field boost).
8. Ecommended Dose–Volume Limits
At present, it is not possible to identify a single best threshold volumetric parameter for
esophageal irradiation, because a wide range of Vdose parameters correlate significantly with
severe acute esophagitis. In particular, the studies we analyzed illustrate a clear trend
demonstrating that volumes receiving >40–50 Gy correlated significantly with acute
esophagitis (Fig. 1) (24). In particular, for high-dose conventionally fractionated non–small-
cell lung cancer treatments, it is prudent to ensure that the dose to even small volumes of the
esophagus does not exceed the prescription dose. This is a particular risk of intensity-
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modulated RT if no esophagus constraints are imposed in the planning process and the
radiation dose is “dumped” inadvertently in the region of the esophagus. The ongoing Phase
III Intergroup trial (RTOG 0617) has recommended (but has not mandated) that the mean
dose to the esophagus be kept to <34 Gy and that the esophageal V60 be calculated for each
patient enrolled in the trial. These recommendations were based on the Washington
University experience (7) (Table 2). An inability to provide specific “dose limits” for the
esophagus in this large cooperative group trial illustrates the lack of evidence that any
absolute limits can be imposed on the basis of current published data. However, from the
clinical reports without detailed dosimetric esophageal dose correlates, it appears safe to
give doses as great as 74 Gy to a segment of the esophagus with concurrent carboplatin and
paclitaxel (36–38).
In the section “Mathematical/Biologic Models,” we described several mathematical models
that correlate with the incidence of Grade 2 or greater acute esophagitis for specific study
populations. Clinicians with appropriate treatment planning resources might find such
models interesting and useful, particularly when making decisions between competing
treatment plans. However, it is important to recognize that, at present, these models are
tentative as best. A prudent approach to using any mathematical model is to first do a
retrospective “test drive” to determine whether predictions are in qualitative agreement with
the complications observed at one's own center, subject to local contouring protocols,
treatment beam arrangements, and patient populations.
9. Future Toxicity Studies
New thoracic protocols that have acute esophagitis toxicity as an endpoint should specify
one or more dose–volume models to test prospectively. Future analyses of esophagitis
should ideally include the time of onset, because the complication occurs from the dose
accumulated during the course of therapy, usually well before the total dose has been
delivered. Complication models could potentially be constructed on the basis of the dose
accumulated each week and the total dose. Thus, the data analysis would not be a continual
cycle of hypothesis/model generation, such as is commonly the case today.
Peer-reviewed treatment planning and outcomes data should be pooled and made
permanently available. This might enable a single analysis to confidently uncover the factors
that lead to such an array of dose–volume correlations, such as seen in Fig. 1, to derive
robust parameter sets for the Lyman or relative seriality models or to derive new semi-
mechanistic models.
The exclusion of the entire esophageal length/volume from the high-dose radiation region is
extremely difficult; however, reducing the radiation dose delivered to a part of esophageal
circumference might be feasible. Intensity-modulated RT seems well suited for that purpose,
with its ability to deliver concave-shaped RT dose distributions around organs at risk (39).
Studies to better understand the importance of the spatial distribution of the dose (and hence
the utility of partial circumferential sparing) would be useful.
Additional study is needed to understand the utility of radioprotectors.
A prospective assessment of the dose and volume and other factors relating to esophageal
injury after hypofractionation is needed, given the growing interest in this approach.
The identification of biologic markers of radiation sensitivity will be important to explain
individual variations in patients' reactions.
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We recommend that the Common Terminology Criteria for Adverse Events, version 3, be
used to score both acute and late injury. It is simple and consistent, and its use has been
mandated by the National Cancer Institute in the cooperative group trials since October 2003
(40). Late injury might be scored under several endpoints, including necrosis, obstruction,
perforation, or stricture, depending on the patient's symptoms.
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Correlations between acute esophagitis and Vx values (volume greater than x Gy). p Values
correlated with relative or absolute volumes (in cubic centimeters); relative volumes used
except as noted for 2006 data from Wei et al. (22). Lower values indicate better correlations
with outcomes. As the wide variety of correlation shapes suggests, there does not appear to
be any singular “threshold” dose above which a toxic effect is observed.
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Incidence of acute esophagitis according to Vx (volume receiving more than x Gy). x-Axis
values estimated according to range of doses reported. Each curve annotated as follows:
Vdose (investigator, number of patients, percentage with concurrent chemotherapy [CCT].
Percentage of patients who received sequential chemotherapy in studies by Ahn et al. (11),
Belderbos et al. (19), and Kim et al. (20) was 44%, 38%, and 15%, respectively. Data for
V50 (Ahn et al. [11]) at 15, 45, and 75 Gy represent reported rates of Grade 2 or greater
acute esophagitis plotted in dose bins at <30%, 30–60%, and >60%, respectively. Similarly,
for V70 (Ahn et al. [11]), V50 (Rodriguez et al. [23]), and V60 (Kim et al. [20]), each symbol
represents rates of acute esophagitis at <10% vs. 11–30% vs. 31–64%, and ≤30% vs. ≥30%,
and ≤30 vs. >30%, respectively. Dashed horizontal lines reflect dose ranges ascribed to each
data point. Upper x-axis range of greatest data point for V50 (Rodriguez et al. [23]), V50
(Ahn et al. [11]), and V60 (Kim et al. [20]), are indefinite according to data (light-gray
dotted bars). Solid and open symbols represent reported rates of Grade 2 or greater acute
esoph-agitis and Grade 3 or greater acute esophagitis, respectively. Thicker and thinner solid
lines represent higher and lower doses of Vx, respectively (i.e., thicker line for V70 and
thinner line for V20).
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Table 2
Three parameterizations of Lyman-Kutcher-Burman model for esophageal complications
Investigator TD50 (Gy) n m
Burman et al. (31), 1991 68 0.06 0.11
Chapet et al. (13), 2005 51 (29–82) 0.44 (0.11–1.41) 0.32 (0.19–0.57)
Belderbos et al. (19), 2005 47 (41–60) 0.69 (0.18–6.3) 0.36 (0.25–0.55)
Abbreviation: TD50= median toxic dose
Burman values derived from “Emami” estimates for more severe endpoint.
Int J Radiat Oncol Biol Phys. Author manuscript; available in PMC 2013 March 05.
